Diagnostics and monitoring in Hymenoptera venom allergy: current and future perspectives

Hymenoptera stings are a major trigger of IgE-mediated anaphylaxis, yet only a minority of exposed individuals develop systemic reactions, making accurate diagnosis essential but complex. This review synthesizes current evidence across clinical, serologic, cellular and molecular diagnostic modalities in Hymenoptera venom allergy. Clinical history and epidemiologic predictors-such as occupation, cumulative sting exposure, reaction latency, comorbidities and quality-of-life impairment, provide crucial context but lack sufficient predictive power when used alone. Skin prick and intradermal testing remain first-line tools due to high sensitivity, although interpretation is limited by interspecies cross-reactivity, extract variability and reduced reliability shortly after a sting. Serum IgE and component-resolved diagnostics improve species identification but are influenced by cross-reactive carbohydrate determinants and cannot reliably predict reaction severity or venom-immunotherapy outcomes. Basal and acute tryptase measurements contribute significantly to risk stratification and detection of clonal mast-cell disorders, though normal values do not exclude severe reactions. Functional assays, including basophil activation testing, histamine-release assays and emerging mast-cell activation platforms, provide dynamic confirmation of effector-cell reactivity in diagnostically challenging cases. Controlled sting challenge remains the reference method for confirming clinical reactivity or protection but is reserved for selected high-risk patients due to inherent procedural risks. Novel biomarkers such as osteopontin, KIT mutations, PGD₂ metabolites, regulatory T-cell signatures and multi-omic molecular profiles offer promising avenues for future refinement. Overall, evidence supports a multimodal, individualized diagnostic strategy integrating clinical context with complementary laboratory and functional tests.